Han Xu Selected Research

Breast Neoplasms (Breast Cancer)

1/2024	Advances in the study of tertiary lymphoid structures in the immunotherapy of breast cancer.
1/2023	CRISPR/Cas9 screen uncovers functional translation of cryptic lncRNA-encoded open reading frames in human cancer.
1/2022	Real-World Outcome and Prognostic Factors Among HER2-Positive Metastatic Breast Cancer Patients Receiving Pyrotinib-Based Therapy: A Multicenter Retrospective Analysis.
1/2022	Application value of modified radical mastectomy in female patients with breast cancer of different molecular types: a prognosis study.
1/2021	Systematic functional interrogation of human pseudogenes using CRISPRi.
1/2020	Eight immune-related genes predict survival outcomes and immune characteristics in breast cancer.
10/2019	Structure-based derivation and intramolecular cyclization of peptide inhibitors from PD-1/PD-L1 complex interface as immune checkpoint blockade for breast cancer immunotherapy.
2/2019	Molecular insight into the T798M gatekeeper mutation-caused acquired resistance to tyrosine kinase inhibitors in ErbB2-positive breast cancer.
1/2019	miR-516a-3p inhibits breast cancer cell growth and EMT by blocking the Pygo2/Wnt signalling pathway.
1/2019	SNHG1 contributes to proliferation and invasion by regulating miR-382 in breast cancer.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Han Xu Research Topics

Disease

65	Neoplasms (Cancer) 04/2024 - 11/2011
20	Breast Neoplasms (Breast Cancer) 01/2024 - 07/2011
9	Inflammation (Inflammations) 02/2024 - 08/2007
8	Neoplasm Metastasis (Metastasis) 04/2021 - 01/2015
5	Body Weight (Weight, Body) 01/2024 - 11/2015
5	Infections 12/2023 - 01/2015
5	Hypertension (High Blood Pressure) 10/2023 - 10/2009
5	Myocardial Ischemia (Ischemic Heart Diseases) 05/2022 - 01/2013
5	Reperfusion Injury 05/2022 - 01/2013
4	Cardiovascular Diseases (Cardiovascular Disease) 07/2024 - 01/2014
4	Carcinogenesis 01/2024 - 01/2015
4	Hepatocellular Carcinoma (Hepatoma) 01/2023 - 01/2019
4	Hypoxia (Hypoxemia) 10/2022 - 01/2013
4	Carcinoma (Carcinomatosis) 01/2022 - 01/2010
4	Ischemia 01/2022 - 03/2006
4	Prostatic Neoplasms (Prostate Cancer) 01/2022 - 12/2012
4	Proteinuria 07/2020 - 07/2009
3	Multiple Myeloma 01/2024 - 09/2014
3	Lymphoma (Lymphomas) 12/2023 - 12/2020
3	Edema (Dropsy) 10/2023 - 07/2011
3	Pain (Aches) 10/2023 - 09/2020
3	Triple Negative Breast Neoplasms 10/2023 - 01/2020
3	Hypersensitivity (Allergy) 11/2014 - 02/2011
3	Pre-Eclampsia (Preeclampsia) 01/2010 - 01/2007
2	Glucose Intolerance 02/2024 - 09/2013
2	Cardiomegaly (Heart Hypertrophy) 02/2024 - 08/2015
2	Hyperglycemia 10/2023 - 07/2020
2	Drug Resistant Epilepsy 12/2022 - 01/2020
2	Anemia 12/2022 - 01/2020
2	Stomach Neoplasms (Stomach Cancer) 05/2022 - 01/2022
2	Infarction (Infarctions) 05/2022 - 11/2019
2	Colorectal Neoplasms (Colorectal Cancer) 01/2022 - 01/2021
2	Atherosclerosis 01/2022 - 01/2014
2	Myocardial Infarction 01/2022 - 01/2021
2	Melanoma (Melanoma, Malignant) 01/2022 - 01/2017
2	Poisoning 10/2021 - 12/2015
2	Starvation 02/2021 - 01/2020
2	Uterine Cervical Neoplasms (Cancer of the Cervix) 12/2020 - 01/2015
2	Hyperthermia 10/2020 - 01/2020

Drug/Important Bio-Agent (IBA)

16	Proteins (Proteins, Gene)FDA Link 02/2024 - 01/2012
11	Biomarkers (Surrogate Marker)IBA 04/2024 - 01/2015
8	Messenger RNA (mRNA)IBA 12/2023 - 07/2015
6	Glucose (Dextrose)FDA LinkGeneric 02/2024 - 11/2015
6	Long Noncoding RNAIBA 12/2023 - 01/2019
5	Estrogens (Estrogen)FDA Link 01/2023 - 03/2006
5	AntigensIBA 01/2022 - 11/2009
4	Reactive Oxygen Species (Oxygen Radicals)IBA 07/2024 - 07/2015
4	CytokinesIBA 02/2024 - 01/2004
4	LipopolysaccharidesIBA 02/2024 - 10/2012
4	EnzymesIBA 01/2024 - 10/2009
4	Transcription Factors (Transcription Factor)IBA 12/2023 - 01/2014
4	CalciumIBA 01/2023 - 01/2013
4	Polysaccharides (Glycans)IBA 12/2022 - 07/2009
4	Cadherins (E-Cadherin)IBA 05/2022 - 01/2018
4	N-n-butyl haloperidol iodideIBA 09/2015 - 08/2012
3	Interleukin-6 (Interleukin 6)IBA 02/2024 - 07/2020
3	Insulin (Novolin)FDA Link 01/2024 - 11/2015
3	InflammasomesIBA 10/2023 - 11/2019
3	Paclitaxel (Taxol)FDA LinkGeneric 10/2023 - 07/2011
3	PolymersIBA 06/2023 - 04/2023
3	Phenobarbital (Luminal)FDA Link 01/2023 - 01/2021
3	Immune Checkpoint InhibitorsIBA 01/2022 - 10/2019
3	Phosphotransferases (Kinase)IBA 01/2020 - 01/2018
3	matriptaseIBA 01/2012 - 01/2010
2	Therapeutic UsesIBA 07/2024 - 02/2019
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 02/2024 - 03/2006
2	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 02/2024 - 01/2018
2	Nitric Oxide Synthase (NO Synthase)IBA 02/2024 - 10/2009
2	MethyltransferasesIBA 01/2024 - 01/2022
2	6-methyladenineIBA 01/2024 - 01/2022
2	Angiotensin-Converting Enzyme 2IBA 12/2023 - 11/2015
2	Amino Acids FDA Link 11/2023 - 02/2019
2	danmuIBA 11/2023 - 11/2022
2	NF-kappa B (NF-kB)IBA 10/2023 - 08/2007
2	Immunologic Factors (Immunomodulators)IBA 02/2023 - 01/2018
2	Estrogen ReceptorsIBA 01/2023 - 01/2018
2	MagnesiumIBA 01/2023 - 04/2021
2	UridineIBA 12/2022 - 01/2020
2	pyrimidineIBA 12/2022 - 02/2019
2	OligosaccharidesIBA 09/2022 - 04/2021
2	Evans Blue (Blue, Evans)FDA Link 05/2022 - 11/2019
2	InterferonsIBA 01/2022 - 01/2020
2	ChemokinesIBA 01/2022 - 01/2022
2	LigandsIBA 01/2022 - 01/2022
2	human ERBB2 proteinIBA 01/2022 - 02/2019
2	Photosensitizing Agents (Photosensitizers)IBA 12/2021 - 10/2020
2	Glutathione (Reduced Glutathione)IBA 02/2021 - 10/2009
2	hydroxide ionIBA 02/2021 - 12/2015
2	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 11/2009
2	GoldIBA 01/2021 - 01/2019
2	Triglycerides (Triacylglycerol)IBA 07/2020 - 11/2015

Therapy/Procedure

34	Therapeutics 07/2024 - 01/2004
6	Immunotherapy 04/2024 - 10/2019
6	Precision Medicine 04/2023 - 11/2018
5	Photothermal Therapy 06/2023 - 11/2018
3	Traction 01/2022 - 06/2018
3	Castration 01/2022 - 12/2012
3	Chinese Traditional Medicine (Traditional Chinese Medicine) 05/2020 - 07/2009
2	Cell- and Tissue-Based Therapy (Cell Therapy) 01/2022 - 01/2022
2	Percutaneous Coronary Intervention 03/2021 - 01/2021